ADDED
ACA Patient Protection and Affordable Care Act, as amended by the Health Care and Education and Reconciliation Act Aculys Pharma Aculys Pharma, Inc.
Adjusted EBITDA Non-GAAP financial measure that the Company believes is appropriate to provide information to investors - EBITDA (defined below) is further adjusted for share-based compensation expense, litigation settlements, and other contingencies, net, gain (loss) on divestitures of businesses, impairment of long-lived assets and goodwill, restructuring, acquisition and divestiture-related and other special items Adjusted EPS Adjusted net earnings per diluted share Administration The current presidential administration in the U.S.
Department of Justice DPDP Act Digital Personal Data Protection Act, 2023 EBITDA Non-GAAP financial measure that the Company believes is appropriate to provide information to investors - U.S.
Upjohn Business Pfizer s off-patent branded and generic established medicines business that, in connection with the Combination, was separated from Pfizer and combined with Mylan to form Viatris Upjohn Distributor Markets Select geographic markets that were part of the Combination that are smaller in nature and in which we had no established infrastructure prior to or following the Combination and that the Company has divested or intends to divest Upjohn U.S.
The Company operates in more than 165 countries and territories with more than 30,000 employees.
The Company has 27 manufacturing, packaging, and distribution sites worldwide, more than 1,400 approved molecules, and what we believe is industry leading commercial, R D, regulatory, manufacturing, legal and medical expertise.
A Strong Foundation for Performance and Impact We believe that Viatris ability to sustainably deliver high-quality medicines is grounded in its mission to empower people worldwide to live healthier at every stage of life.
Viatris has executed various strategic initiatives, transactions and business arrangements over the last few years to return its base business to growth, deliver on its pipeline, reduce debt, and return capital to shareholders.
The Company has also completed certain divestiture-related transactions to simplify and streamline its business, accelerate paydown of debt and unlock value as discussed below.
In November 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics to create a vertically integrated global biosimilars leader, for a combination of cash and stock in the form of CCPS representing a stake of approximately 12.9% (on a fully diluted basis) in Biocon Biologics.
REMOVED
Department of Justice EBITDA Non-GAAP financial measure that the Company believes is appropriate to provide information to investors - U.S.
District Court for the Eastern District of Pennsylvania EMA European Medicines Agency Emerging Markets segment Viatris business segment that includes, but is not limited to, our operations primarily in the following markets: Parts of Asia, the Middle East, South and Central America, Africa, and Eastern Europe EPD Business Abbott Laboratories non-U.S.
Idorsia Transaction The transaction between Viatris and Idorsia pursuant to which Viatris acquired the development programs and certain personnel related to selatogrel and cenerimod from Idorsia in exchange for an upfront payment to Idorsia of $350 million, potential development and regulatory milestone payments, certain contingent payments of tiered sales milestones, as well as potential contingent tiered sales royalties INN International Nonproprietary Name IPR D In-process research and development IRS U.S.
Lexicon LIBOR London Interbank Offered Rate LOE Loss of exclusivity Mapi Mapi Pharma Ltd.
Profit Sharing 401(k) Plan 401(k) retirement plan with a profit sharing component for non-union represented employees PSUs Performance awards QCE Quality consistency evaluation R D Research and development Receivables Facility The $400 million accounts receivable facility entered into in August 2020 and expiring in April 2025 Registered Upjohn Notes The 2.300% Senior Notes due 2027, 2.700% Senior Notes due 2030, 3.850% Senior Notes due 2040 and 4.000% Senior Notes due 2050 originally issued on October 29, 2021 registered with the SEC in exchange for the corresponding Unregistered Upjohn U.S.
Upjohn Business Pfizer s off-patent branded and generic established medicines business that, in connection with the Combination, was separated from Pfizer and combined with Mylan to form Viatris Upjohn Distributor Markets Select geographic markets that were part of the Combination that are smaller in nature and in which we had no established infrastructure prior to or following the Combination and that the Company has divested or intends to divest Upjohn Euro Notes Senior unsecured notes denominated in euros and issued by Upjohn Finance B.V.
The Company operates in more than 165 countries and territories with approximately 32,000 employees.
The Company has 26 manufacturing and packaging sites worldwide, more than 1,400 approved molecules, and industry leading commercial, R D, regulatory, manufacturing, legal and medical expertise.
Viatris has executed various strategic initiatives, transactions and business arrangements over the last few years to return its base business to growth, deliver on its pipeline, reduce debt, maintain an investment grade credit rating and return capital to shareholders.
The Company has also completed certain transactions to simplify and streamline its business, accelerate paydown of debt and unlock value, including the Biocon Biologics Transaction and the recently completed divestitures discussed below.